Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Dupixent late-breaking positive phase 3 data in chronic spontaneous ...
Dupixent phase 3 LIBERTY-CUPID Study C results show significant reduction in itch and urticaria activity scores, with higher disease control rates in chronic spontaneous urticaria patients on antihistamines, to be presented at ACAAI 2024.
Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous
Dupixent significantly reduced itch and hive activity in uncontrolled chronic spontaneous urticaria patients, with 41% achieving well-controlled disease status. Positive Phase 3 LIBERTY-CUPID Study C data support potential U.S. regulatory resubmission by year-end, aiming for Dupixent to be the first new targeted treatment for CSU in over 10 years.
Federal Circuit Denies Injunction Pending Appeal After Amgen Beat Preliminary
Federal Circuit denies Regeneron's request for injunction pending appeal against Amgen's biosimilar aflibercept launch, expediting the case for January 2025 oral arguments.
XLV: 3 Healthcare ETFs to Buy for Defensive Growth
Healthcare ETFs like iShares Biotechnology ETF (IBB), Vanguard Health Care Index Fund ETF Shares (VHT), and Health Care Select Sector SPDR Fund (XLV) offer stability and growth. Factors such as aging population, chronic diseases, and workforce shortages drive higher demand. Q3 2024 saw the largest M&A activity in healthcare, with $13.30 billion in transactions. AI investments and digital health innovations are boosting the sector, with the global AI in healthcare market projected to reach $148.40 billion by 2029.
Regeneron, Sanofi announce presentation of Dupixent Phase 3 data in CSU
Regeneron and Sanofi presented Phase 3 LIBERTY-CUPID Study C data on Dupixent's efficacy in uncontrolled chronic spontaneous urticaria patients receiving antihistamines, showing significant itch and urticaria activity score reductions and higher well-controlled disease status rates compared to placebo. The data was presented at the ACAAI 2024 Annual Scientific Meeting. Dupixent's safety profile was consistent with its dermatological indications, with similar treatment emergent adverse event rates for Dupixent and placebo. Dupixent is approved for CSU in Japan and UAE, under review in EU, but not fully evaluated elsewhere.
Approval of Bevacizumab Biosimilar Could Eliminate Access to Low-Cost AMD Therapy
FDA approval of a bevacizumab biosimilar for ophthalmic use could eliminate low-cost off-label treatment options, leading to a $457 million increase in Medicare costs and $117 million in patient costs annually.
Amgen set for 'at-risk' launch of blockbuster eye drug biosimilar
Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected. Regeneron has filed multiple suits over rivals’ copies of aflibercept.
Biotechnology Market Size, Share and Statistics - 2034
The global biotechnology market is projected to grow from US$ 550.83 billion in 2024 to US$ 2667.36 billion by 2034, driven by advancements in synthetic biology, CRISPR gene editing, and genomic sequencing. Increasing health issues and genetic abnormalities are boosting demand for biopharmaceuticals. North America leads in market share, while India's agricultural biotechnology sector is rapidly expanding.
Legal win leads Amgen to at-risk launch of Eylea biosimilar
Amgen plans to launch its biosimilar of Regeneron's Eylea in the US despite ongoing patent infringement litigation, with potential risks and rewards. The US Court of Appeals lifted a temporary injunction, prompting Amgen's decision. Regeneron maintains Amgen's infringement belief and appeals process continues, with oral arguments set for January. Eylea, approved for various eye diseases, faces competition from Roche's Vabysmo.
© Copyright 2024. All Rights Reserved by MedPath